The Viscosupplementation industry is expected to expand lucratively to an estimated value of US$ 10.16 Billion by 2033, from US$ 4.66 Billion in 2024. This expansion reflects a compound annual growth rate (CAGR) of 9.02% between 2025 and 2033.
An intraarticular injection of a gel-like fluid called exogenous hydraulic acid (HA) derivatives is given directly into the patient's knee joints during a minimally invasive medical treatment called viscosupplementation. It reduces inflammation, acts as a shock absorber for joint loads, and lubricates bones so they may glide over one another. Viscosupplementation minimizes excruciating pain, helps the synovial fluids provide more cushion, decreases friction during movements, and increases the joint's range of motion. In addition, it restores the synovial fluids' rheological characteristics, which have chondroprotective, mechanical, analgesic, and anti-inflammatory benefits. Because of this, viscosupplementation is widely used to treat osteoarthritis in the hands, knees, and hips.
Headquarters: United Kingdom
Revenue: $5.8B in 2023
The medical technology company Smith & Nephew Plc (Smith & Nephew) develops, manufactures, and markets medical devices for advanced wound care, sports medicine, orthopedic reconstruction and trauma, and ENT. It offers sophisticated products and equipment for hip, knee, and shoulder replacement systems, soft tissue repair or removal, robotics-assisted and digital enabling solutions, wound dressings, advanced wound bio-actives, and advanced wound devices. The company provides its products to surgeons, nurses and nurse specialists, physicians and general practitioners, purchasing professionals in hospitals, and healthcare insurers under the brands Oasis, Opsite, Pico, Primapore, Profore, and Renasys, among others. The company sells its products across Europe, the Americas, Asia Pacific, Africa, and the Middle East. The headquarters of Smith & Nephew are situated in Watford, Hertfordshire, in the United Kingdom.
Headquarters: Switzerland
The biotechnology company F. Hoffmann-La Roche Ltd. (Roche) provides innovative, state-of-the-art medicines for several significant disease areas in addition to in-vitro diagnostics. It provides drugs to treat a wide range of conditions, including as cancer, autoimmune diseases, central nervous system disorders, ocular disorders, infectious diseases, and respiratory disorders. The company also offers in-vitro diagnostics, tissue-based cancer diagnoses, and diabetes management solutions. Roche conducts research to discover novel approaches to sickness diagnosis, treatment, and prevention. Among the customers the company provides its products and services to include hospitals, medical professionals, commercial labs, researchers, and pharmacists. Basel, Switzerland, is home to Roche's headquarters.
Headquarters: France
Revenue: $47.9B in 2023
Sanofi is a healthcare company that conducts research, develops, produces, and distributes a range of drugs and vaccines. Human immunizations against various bacterial and viral diseases, drugs to treat cancer, rare diseases, and multiple sclerosis, and other products are all part of its product line. The company also distributes consumer health products for women's health, including vitamins, minerals, and supplements, as well as products for sinusitis, pain, colds, coughs, and flu. Sanofi's research and development efforts are focused on creating new biologics formulations to produce precision drugs and on creating a combination drug to increase treatment efficacy. It has operations across Africa, the Americas, Europe, Asia-Pacific, and the Middle East. Sanofi's headquarters are situated in Paris, on the Ile-de-France in France.
Chugai Pharmaceutical Co.
Establishment: 1925
Headquarters: Japan
Revenue: $8.1B in 2023
Chugai Pharmaceutical Co. Ltd. (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd., is primarily concerned with biotechnological research and pharmaceutical manufacturing. The company manufactures, markets, exports, and imports pharmaceutical products in Japan and other countries. Products from the company are used to treat a variety of illnesses, including cancer, diseases of the kidneys, immune systems, bones and joints, and infectious infections. It also offers drugs to support kidney, liver, and other organ transplants. Through its network of subsidiaries, the company sells its pharmaceutical products in foreign markets in North America, Europe, and Asia. Chugai's headquarters are in Chuo-ku, Tokyo, Japan.
Headquarters: United States
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) that is well-known for its expertise in complex injectable treatments. For than 40 years, the company has led the globe in pharmaceutical-grade sodium hyaluronate (NaHy) production, with a focus on developing and manufacturing extremely viscous solutions. Lifecore supports pharmaceutical and biotech partners from the early stages of formulation to commercialization by offering tailored solutions for difficult-to-formulate and aseptically filled pharmaceutical products. By satisfying crucial needs across the medication research and production lifecycle, Lifecore - renowned for its state-of-the-art expertise and all-encompassing support - is crucial to successfully and safely bringing challenging treatments to market.
An intraarticular injection of a gel-like fluid called exogenous hydraulic acid (HA) derivatives is given directly into the patient's knee joints during a minimally invasive medical treatment called viscosupplementation. It reduces inflammation, acts as a shock absorber for joint loads, and lubricates bones so they may glide over one another. Viscosupplementation minimizes excruciating pain, helps the synovial fluids provide more cushion, decreases friction during movements, and increases the joint's range of motion. In addition, it restores the synovial fluids' rheological characteristics, which have chondroprotective, mechanical, analgesic, and anti-inflammatory benefits. Because of this, viscosupplementation is widely used to treat osteoarthritis in the hands, knees, and hips.
List of Leading Companies in the Viscosupplementation Market
Smith & Nephew PLC
Establishment: 1856Headquarters: United Kingdom
Revenue: $5.8B in 2023
The medical technology company Smith & Nephew Plc (Smith & Nephew) develops, manufactures, and markets medical devices for advanced wound care, sports medicine, orthopedic reconstruction and trauma, and ENT. It offers sophisticated products and equipment for hip, knee, and shoulder replacement systems, soft tissue repair or removal, robotics-assisted and digital enabling solutions, wound dressings, advanced wound bio-actives, and advanced wound devices. The company provides its products to surgeons, nurses and nurse specialists, physicians and general practitioners, purchasing professionals in hospitals, and healthcare insurers under the brands Oasis, Opsite, Pico, Primapore, Profore, and Renasys, among others. The company sells its products across Europe, the Americas, Asia Pacific, Africa, and the Middle East. The headquarters of Smith & Nephew are situated in Watford, Hertfordshire, in the United Kingdom.
F.Hoffmann-La Roche Ltd
Establishment: 1896Headquarters: Switzerland
The biotechnology company F. Hoffmann-La Roche Ltd. (Roche) provides innovative, state-of-the-art medicines for several significant disease areas in addition to in-vitro diagnostics. It provides drugs to treat a wide range of conditions, including as cancer, autoimmune diseases, central nervous system disorders, ocular disorders, infectious diseases, and respiratory disorders. The company also offers in-vitro diagnostics, tissue-based cancer diagnoses, and diabetes management solutions. Roche conducts research to discover novel approaches to sickness diagnosis, treatment, and prevention. Among the customers the company provides its products and services to include hospitals, medical professionals, commercial labs, researchers, and pharmacists. Basel, Switzerland, is home to Roche's headquarters.
Sanofi
Establishment: 1973Headquarters: France
Revenue: $47.9B in 2023
Sanofi is a healthcare company that conducts research, develops, produces, and distributes a range of drugs and vaccines. Human immunizations against various bacterial and viral diseases, drugs to treat cancer, rare diseases, and multiple sclerosis, and other products are all part of its product line. The company also distributes consumer health products for women's health, including vitamins, minerals, and supplements, as well as products for sinusitis, pain, colds, coughs, and flu. Sanofi's research and development efforts are focused on creating new biologics formulations to produce precision drugs and on creating a combination drug to increase treatment efficacy. It has operations across Africa, the Americas, Europe, Asia-Pacific, and the Middle East. Sanofi's headquarters are situated in Paris, on the Ile-de-France in France.
Chugai Pharmaceutical Co.
Establishment: 1925
Headquarters: Japan
Revenue: $8.1B in 2023
Chugai Pharmaceutical Co. Ltd. (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd., is primarily concerned with biotechnological research and pharmaceutical manufacturing. The company manufactures, markets, exports, and imports pharmaceutical products in Japan and other countries. Products from the company are used to treat a variety of illnesses, including cancer, diseases of the kidneys, immune systems, bones and joints, and infectious infections. It also offers drugs to support kidney, liver, and other organ transplants. Through its network of subsidiaries, the company sells its pharmaceutical products in foreign markets in North America, Europe, and Asia. Chugai's headquarters are in Chuo-ku, Tokyo, Japan.
Lifecore Biomedical
Establishment: 1965Headquarters: United States
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) that is well-known for its expertise in complex injectable treatments. For than 40 years, the company has led the globe in pharmaceutical-grade sodium hyaluronate (NaHy) production, with a focus on developing and manufacturing extremely viscous solutions. Lifecore supports pharmaceutical and biotech partners from the early stages of formulation to commercialization by offering tailored solutions for difficult-to-formulate and aseptically filled pharmaceutical products. By satisfying crucial needs across the medication research and production lifecycle, Lifecore - renowned for its state-of-the-art expertise and all-encompassing support - is crucial to successfully and safely bringing challenging treatments to market.
SWOT Analysis of Viscosupplementation Market
LG Life Sciences Ltd Strength Analysis
Comprehensive R&D and Manufacturing Capabilities
LG Chem's Life Sciences division boasts a robust infrastructure encompassing the entire pharmaceutical value chain - from research and development to manufacturing and commercialization. This integrated approach enables the company to efficiently develop and scale innovative therapies, ensuring quality control and timely delivery to global markets. The division's diverse portfolio includes biologics, vaccines, and specialty chemicals, underpinned by a strong commitment to scientific advancement and regulatory compliance. Such comprehensive capabilities position LG Chem as a formidable player in the global life sciences sector, capable of addressing complex healthcare challenges and meeting the evolving needs of patients worldwide.LG Life Sciences Ltd Opportunity Analysis
Expansion into Emerging Biopharmaceutical Markets
The global biopharmaceutical industry is experiencing significant growth, driven by advancements in personalized medicine, biologics, and gene therapies. LG Chem's Life Sciences division has the opportunity to capitalize on this trend by expanding its presence in emerging markets such as Southeast Asia, Latin America, and Africa. By leveraging its existing R&D and manufacturing infrastructure, LG Chem can introduce its innovative therapies to regions with increasing healthcare demands and improving access to medical treatments. Strategic partnerships, local collaborations, and tailored market entry strategies will be crucial in establishing a strong foothold and driving sustainable growth in these high-potential markets.DePuy Synthes Strength Analysis
Comprehensive Orthopedic Portfolio
DePuy Synthes, a part of Johnson & Johnson MedTech, boasts one of the most extensive orthopedic product portfolios globally. Their offerings span joint reconstruction, trauma, spine, craniomaxillofacial, sports medicine, and enabling technologies. This breadth allows them to serve a wide range of surgical needs, providing integrated solutions that enhance patient outcomes. The company's commitment to innovation is evident in its continuous development of advanced surgical tools and technologies, such as the VELYS™ Robotic-Assisted Solution and the ATTUNE™ Knee System. These innovations not only improve surgical precision but also contribute to faster recovery times for patients. DePuy Synthes' strong brand reputation and extensive product range solidify its position as a leader in the orthopedic medical device industry.DePuy Synthes Opportunity Analysis
Expansion in Emerging Markets
With the global orthopedic device market experiencing significant growth, DePuy Synthes has a substantial opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are witnessing an increase in orthopedic procedures due to aging populations, rising healthcare awareness, and improving healthcare infrastructure. By leveraging Johnson & Johnson's established networks and resources, DePuy Synthes can introduce its advanced orthopedic solutions to these markets, addressing the growing demand for quality healthcare. Strategic partnerships, localized marketing strategies, and tailored product offerings can facilitate market entry and expansion. This approach not only broadens DePuy Synthes' global footprint but also contributes to improving healthcare outcomes in underserved regions.Fidia Farmaceutici S.p.A Strength Analysis
Leadership in Hyaluronic Acid Innovation
Fidia Farmaceutici S.p.A. has established itself as a global leader in hyaluronic acid (HA) technology, holding approximately 1,500 patents, with about 1,250 dedicated to HA production. This extensive intellectual property portfolio underpins the company's dominance in viscosupplementation, ophthalmology, and wound care markets. Fidia's commitment to research and development has led to the creation of advanced HA-based products, enhancing patient outcomes and solidifying its position in the pharmaceutical industry. The company's innovative approach and robust patent portfolio provide a competitive edge, enabling Fidia to maintain leadership in the HA sector and expand its influence across various therapeutic areas.Fidia Farmaceutici S.p.A Opportunity Analysis
Expansion into Emerging Biopharmaceutical Markets
Fidia Farmaceutici S.p.A. has significant growth opportunities by expanding its presence in emerging biopharmaceutical markets, particularly in regions like Asia-Pacific, Latin America, and Africa. These areas are experiencing increased healthcare demands due to aging populations and rising incidences of chronic diseases. By leveraging its expertise in hyaluronic acid technology and existing product portfolio, Fidia can introduce its innovative therapies to these markets, addressing unmet medical needs. Strategic partnerships, local manufacturing, and tailored marketing strategies can facilitate market entry and expansion, allowing Fidia to tap into high-growth regions and enhance its global footprint.Recent Developments of Viscosupplementation Market
- Anika Therapeutics sharpened its focus on hyaluronic acid pain relief in March 2025 by closing the sale of Parcus Medical to Medacta Group.
- For USD 45 million with dependent earn-outs, Bioventus sold its Advanced Rehabilitation division to Accelmed Partners in October 2024.
- VISCO3, a three-injection high molecular weight hyaluronate treatment for moderate-stage knee osteoarthritis, was introduced by Zimmer Biomet in a few international countries in January 2024. Data from clinical trials revealed a positive safety profile, prolonged alleviation for up to six months, and a 52% decrease in pain at 12 weeks.
Viscosupplementation Market & Forecast
- Historical Trends
- Forecast Analysis
Market Share Analysis
Company Analysis
Overview
- Company History and Mission
- Business Model and Operations
- Workforce
Key Persons
- Executive Leadership
- Operational Management
- Division Leaders
- Board Composition
Recent Development & Strategies
- Mergers & Acquisitions
- Partnerships
- Investments
Sustainability Analysis
- Renewable Energy Adoption
- Energy-Efficient Infrastructure
- Use of Sustainable Packaging Materials
- Water Usage and Conservation Strategies
- Waste Management and Circular Economy Initiatives
Product Analysis
- Product Profile
- Quality Standards
- Product Pipeline
- Product Benchmarking
Strategic Assessment: SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Revenue Analysis
The above information will be available for all the following companies:
- Anika Therapeutics Inc.
- Zimmer Biomet
- Smith & Nephew PLC
- F.Hoffmann-La Roche Ltd
- Sanofi
- Chugai Pharmaceutical Co
- Lifecore Biomedical
- LG Life Sciences Ltd
- DePuy Synthes
- Fidia Farmaceutici S.p.A
- Seikagaku Corp.
- Ferring Pharmaceuticals B.V.
- Wellchem Pharmaceuticals Pte Ltd
- OrthogenRx, Inc.
- Bioventus LLC
Table of Contents
1. Viscosupplementation Market1.1 Historical Trends
1.2 Forecast Analysis
2. Market Share Analysis - Viscosupplementation Market
3. Anika Therapeutics Inc.
3.1 Overview
3.1.1 Company History and Mission
3.1.2 Business Model and Operations
3.1.3 Workforce
3.2 Key Persons
3.2.1 Executive Leadership
3.2.2 Operational Management
3.2.3 Division Leaders
3.2.4 Board Composition
3.3 Recent Development & Strategies
3.3.1 Mergers & Acquisitions
3.3.2 Partnerships
3.3.3 Investments
3.4 Sustainability Analysis
3.4.1 Renewable Energy Adoption
3.4.2 Energy-Efficient Infrastructure
3.4.3 Use of Sustainable Packaging Materials
3.4.4 Water Usage and Conservation Strategies
3.4.5 Waste Management and Circular Economy Initiatives
3.5 Product Analysis
3.5.1 Product Profile
3.5.2 Quality Standards
3.5.3 Product Pipeline
3.5.4 Product Benchmarking
3.6 Strategic Assessment: SWOT Analysis
3.6.1 Strengths
3.6.2 Weaknesses
3.6.3 Opportunities
3.6.4 Threats
3.7 Revenue Analysis
Companies Mentioned
- Anika Therapeutics Inc.
- Zimmer Biomet
- Smith & Nephew PLC
- F.Hoffmann-La Roche Ltd
- Sanofi
- Chugai Pharmaceutical Co
- Lifecore Biomedical
- LG Life Sciences Ltd
- DePuy Synthes
- Fidia Farmaceutici S.p.A
- Seikagaku Corp.
- Ferring Pharmaceuticals B.V.
- Wellchem Pharmaceuticals Pte Ltd
- OrthogenRx, Inc.
- Bioventus LLC
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | September 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 4.66 Billion |
| Forecasted Market Value ( USD | $ 10.16 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
